OncoMatch/Clinical Trials/NCT06290193
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Is NCT06290193 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Acute Normovolemic Hemodilution/ANH for ovarian cancer.
Treatment: Acute Normovolemic Hemodilution/ANH — Participants will be scheduled for primary cytoreductive surgery as part of their standard care. Before surgery, participants will be assigned by chance to a study group. Depending on which group they are in, they will receive either acute normovolemic hemodilution/ANH during surgery or standard surgical management during surgery. The researchers think acute normovolemic hemodilution/ANH may decrease the need for allogenic blood transfusion/ABT in people having primary cytoreductive surgery.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Disease stage
Required: Stage IIIC, IV
Lab requirements
Blood counts
platelet count ≥100,000/mcL, INR ≤1.5 (if not on coumadin), preoperative hemoglobin concentration ≥10 mg/dl within 45 days of surgery
Kidney function
creatinine ≤1.6 mg/dl
Liver function
bilirubin ≤2 mg/dl, ALT ≤75 U/L in the absence of biliary tract obstruction
Cardiac function
no active coronary artery disease unless stress study shows no reversible ischemia and normal LV function within 45 days of surgery; no history of congestive heart failure; no uncontrolled hypertension
Preoperative hemoglobin concentration ≥10 mg/dl within 45 days of surgery; Abnormal coagulation parameters (INR >1.5 not on coumadin, or platelet count <100,000 mcL); Evidence of hepatic metabolic disorder (bilirubin >2 mg/dl, ALT >75 U/L in the absence of biliary tract obstruction); A history of renal dysfunction (Cr >1.6 mg/dl); A history of active coronary artery disease; A history of congestive heart failure; A history of uncontrolled hypertension
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited protocol activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited protocol activities) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited protocol activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06290193 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage IIIC or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages